HC Wainwright & Co. maintains Elicio Therapeutics at Buy, lowers price target to $21 from $23

HC Wainwright & Co. maintained its Buy rating for Elicio Therapeutics but lowered its price target to $21 from $23, an 8.7% decrease. The new target implies a 1176.6% upside from the Nov 9 close of $1.65.

Original reporting
Published Nov 10, 2026, 11:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 11:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. maintains Elicio Therapeutics at Buy, lowers price target to $21 from $23 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The downgrade may trigger short‑term selling pressure but also highlights a substantial upside if the company meets expectations.

02

Market read

Analyst price‑target reduction is a modest catalyst for a micro‑cap biotech, offering limited but actionable insight for short‑term traders.

03

What to watch

Potential upcoming clinical data or partnership announcements could offset the price‑target cut.

Relevance 5/10Novelty 5/10Timing: today

Background

Elicio Therapeutics is a micro‑cap biotech whose valuation is highly sensitive to analyst opinions and trial outcomes.

Market effects

May weigh on other small‑cap biotech stocks as analysts tighten targets.

Limited to U.S. biotech sector.

Low

Counterpoint

The large upside implied by the current price could attract contrarian buyers despite the downgrade.

Key entities

  • HC Wainwright & Co.

    Equity research firm that issued the price‑target change.

  • Elicio Therapeutics

    Biotech firm subject of the analyst downgrade.

Related articles

$ELTXHigh

Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • AMPLIFY-7P Phase 2 pre-specified analyses demonstrate substantial reductions in risk of recurrence or death in ctDNA negative patients and patients without prior radiation, enabling a

$ELTXHighAI 8/10

Elicio’s pancreatic cancer vaccine misses primary endpoint

Elicio Therapeutics (ELTX) reported that its Phase 2 study of camupepimut for pancreatic cancer did not meet the primary endpoint of disease-free survival. The study had a hazard ratio of 0.85, missing the target. Subgroup analyses showed potential benefits in patients without baseline ctDNA positivity. The company plans to discuss findings with the FDA for a potential Phase 3 study.

$ELTXMedAI 9/10

99% of evaluable treated patients showed immune responses to a cancer mutation. The trial missed its main goal.

Elicio Therapeutics (ELTX) reported Phase 2 trial results for camupepimut (ELI-002 7P) in pancreatic cancer, missing the primary DFS endpoint but showing favorable trends in subgroups. Key findings: 99% of patients showed immune responses, and DFS improvements were observed in ctDNA-negative (HR 0.51) and ctDNA-positive (HR 0.57) patients. The company plans to discuss Phase 3 study design with the FDA.

$ELTXLow

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Elicio Therapeutics, Inc. (ELTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an a